A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Clinical trial NCT06585644 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06585644
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer (NSCLC)

Start date: 2024-10-01
Primary completion: 2025-11-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.